News | EP Lab | October 30, 2015

Boston Scientific Announces CE Mark For MRI-compatible ICD, CRT-D Labeling

Updated labeling allows backwards-compatibility for MRI scans, improving device longevity

Boston Scientific, CE Mark, MRI conditional labeling, CRT-Ds, ICDs

X4 CRT-D system image courtesy of Boston Scientific


October 30, 2015 — Boston Scientific Corp. has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and Mini implantable cardioverter defibrillator (ICD) and the X4 cardiac resynchronization therapy defibrillator (CRT-D) systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.

Patients with implantable cardiac devices have a wide variety of diagnostic imaging available to them, including X-rays and computed tomography (CT) scans, but Boston Scientific systems had not been evaluated as MRI conditional. This new system labeling, referred to as ImageReady MR Conditional devices, stipulates the conditions under which the systems are considered safe for use in a MRI setting.

"While the broader imaging compatibility will be important for some patients, I still expect device longevity and the ability to mitigate risk of complications to be the most critical factors in choosing the best system for each patient," said Gianluca Botto, head of electrophysiology and clinical arrhythmias at S. Anna Hospital, Como, Italy and president of Italian Association of Pacing and Arrhythmias. 

Boston Scientific said that it is seeking regulatory approvals for revised labeling and updated software for systems using its EnduraLife battery technology in major markets by 2017.

ImageReady capabilities will be added to virtually all high-voltage products currently marketed, including Autogen, Dynagen, Inogen and Origen devices, as well as Acuity X4 quadripolar left ventricular (LV) leads, Ingevity and Fineline II pacing leads, and Reliance 4-Site  and 4-Front defibrillator leads.

For more information: www.bostonscientific.com


Related Content

News | EP Lab

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its ...

Home January 29, 2026
Home
News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
Subscribe Now